Release of levetiracetam from extended-release tablets that appear intact in patient stool.
University of Maryland, Department of Pharmaceutical Sciences, Baltimore, MD, United States.
Soundarya
S
Vaithianathan
University of Maryland, Department of Neurology, Baltimore, MD, United States. Electronic address: tting@som.umaryland.edu.
Tricia Y
TY
Ting
Food and Drug Administration, White Oak, MD, United States.
Wenlei
W
Jiang
University of Maryland, Department of Pharmaceutical Sciences, Baltimore, MD, United States. Electronic address: jpolli@rx.umaryland.edu.
James E
JE
Polli
D000927:Anticonvulsants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D005243:Feces; D006801:Humans; D000077287:Levetiracetam; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D013607:Tablets / Q000008:administration & dosage / Q000493:pharmacokinetics
D000927:Anticonvulsants; D003692:Delayed-Action Preparations; D013607:Tablets; D000077287:Levetiracetam; D010889:Piracetam
Extended-release; Generic; Levetiracetam; Remnant; Stool; Tablet